謝 茂志

Medicine & Life Sciences

1. Stomach Neoplasms 100%
2. Gastrectomy 44%
3. Stomach 41%
4. Adenocarcinoma 41%
5. Survival 38%
6. Neoplasm Metastasis 36%
7. Neoplasms 31%
8. Carcinoma 28%
9. Induced Hyperthermia 28%
10. Lymph Nodes 26%
11. Cytoreduction Surgical Procedures 23%
12. Taiwan 19%
13. Recurrence 18%
14. Peritoneal Neoplasms 18%
15. Survival Rate 15%
16. Gastric Stump 10%
17. Morbidity 10%
18. Pseudomyxoma Peritonei 10%
19. Lymph Node Excision 9%
20. Signet Ring Cell Carcinoma 9%
21. Adjuvant Chemotherapy 8%
22. Drug Therapy 8%
23. Anastomotic Leak 8%
24. Mortality 7%
25. Chemoradiotherapy 7%
26. Risk Management 7%
27. Randomized Controlled Trials 6%
28. Multivariate Analysis 6%
29. Breast Neoplasms 6%
30. Dissection 6%
31. Therapeutics 6%
32. Splenectomy 6%
33. Veterans Hospitals 6%
34. Bazex-Dupre-Christol syndrome 5%
35. Confidence Intervals 5%
36. Breast 5%
37. Abdominal Abscess 5%
38. Liver 5%
39. Adjuvant Chemoradiotherapy 5%
40. Serous Membrane 5%
41. Adjuvant Radiotherapy 5%
42. Disease-Free Survival 5%
43. Tissue Polypeptide Antigen 5%
44. Hepatocellular Carcinoma 5%
45. Colorectal Neoplasms 5%
46. Urachus 5%